Avalo Therapeutics (AVTX) Receivables - Other (2016 - 2024)

Avalo Therapeutics (AVTX) has 8 years of Receivables - Other data on file, last reported at -$387000.0 in Q4 2024.

• Quarterly Receivables - Other rose 72.4% year-over-year to -$387000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$3.0 million (up 28.92% YoY) and the FY2024 annual result came in at $611000.0, up 134.27% from the prior year.
• Receivables - Other slipped to -$387000.0 in Q4 2024, from $998000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $2.5 million in Q3 2021 to a low of -$2.3 million in Q1 2022.
• A 5-year average of $574300.8 and a median of $998000.0 in 2021 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2020 — Receivables - Other jumped 3477.07% — and 2024, when it plunged 1766.67%.
• Tracing AVTX's Receivables - Other over 5 years: stood at -$2.1 million in 2020, then soared by 160.76% to $1.3 million in 2021, then sank by 52.06% to $605000.0 in 2022, then tumbled by 331.74% to -$1.4 million in 2023, then soared by 72.4% to -$387000.0 in 2024.
• The last three Receivables - Other figures came in at -$387000.0 (Q4 2024), $998000.0 (Q3 2024), and -$100000.0 (Q2 2024), per Business Quant data.